Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study

Abstract

A good agreement was found between pFBB and FDG data as obtained by subjective visual and quantitative analyses. Dual-point FBB PET scans could offer complementary information (similar to that from FDG PET and FBB PET) in a single procedure, considering pFBB as a surrogate of FDG.

Multivariate analysis of dual-point amyloid PET intended to assist the diagnosis of Alzheimer’s disease

“…The acquisition of eFBB data started immediately after the radiotracer injection whereas sFBB data was acquired 90 minutes after the radiotracer injection. Both acquisitions lasted for 20 minutes [10]. The 18 F-FDG PET examination was conducted according to internationally accepted criteria [12], resulting in one neuroimage showing the brain metabolism.…”

“…Indeed, most of amyloid radiotracers are lipophilic agents, which are commonly used to assess the regional cerebral blood flow (rCBF), thus their early acquisition could be used to estimate the regional cerebral metabolic rate of glucose (rCMRglc), closely related to rCBF. The second neuroimage would be acquired according to the kinetics of the radiotracer and would allow us to assess the potential brain amyloid deposits [10].…”

Multivariate Approaches in Neuroimaging: Assessing the Connectome of Alzheimer’s Disease

“…The papers in this issue focus on exploring changes in brain connectivity caused by neurodegenerative disorders such as AD; prediction or evolution from mild cognitive impairment (MCI) to AD; and characterization of AD by multivariate approaches. In this sense, the fields of research covered in the issue are vast: from a theoretical point of view [1][2][3][4] by proposing models for neurodegeneration; at the clinical level [5][6][7] by assessing novel treatments, image acquisition protocols, and genetic biomarkers; to the recent advances in machine learning for the diagnosis and prognosis of AD [8][9][10][11].…”

“…At the clinical level, biomarkers of neurodegeneration play a major role in the diagnosis of AD. A novel clinical procedure is proposed in [5] to obtain information on both amyloid-␤ (A␤) accumulation (e.g., from amyloid PET) and downstream neuronal injury (e.g., from FDG-PET) using a single acquisition. The parallelism between brain perfusion and glucose metabolism allows to evaluate whether brain perfusion estimated in a dual-point protocol of FBB-PET can be a surrogate of FDG, using the area under the ROC curve as criterion.…”

“…This mini-forum also includes another clinical study related to the loss of body weight in late-life that is known to occur at a very early stage of AD [6]. As in [5], composite cortical [ 18 F]-AV45 and [ 18 F]-FDG uptakes are considered as surrogates of cortical A␤ load and glucose metabolism, respectively. The relationships between these PET biomarkers with body mass index, present cognitive performance, and cognitive changes over time, were analyzed in this study.…”